Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Evaluation and management of stroke Cucchiara BLHematology Am Soc Hematol Educ Program 2009[]; ä (ä): 293-301In contrast to myocardial infarction, stroke is a heterogeneous disease with multiple different causes. Determination of stroke mechanism is critical to choosing optimal therapy to prevent recurrence. This article reviews the diagnostic approach to stroke and prognostic and treatment implications of specific stroke mechanisms. Data on the role of antiplatelet and anticoagulant therapy in secondary stroke prevention, as well as the role of these agents and thrombolytic therapy in acute stroke treatment are reviewed. Situations of particular relevance to the practicing hematologist-stroke in the young, patients with multiple recurrent strokes, patients with abnormal hypercoagulable laboratory testing, and treatment of intracerebral hemorrhage following thrombolytic therapy-are discussed.|*Stroke/classification/diagnosis/drug therapy/etiology/prevention & control/surgery[MESH]|Adolescent[MESH]|Adult[MESH]|Age Factors[MESH]|Aged[MESH]|Anticoagulants/adverse effects/therapeutic use[MESH]|Arteriosclerosis/complications[MESH]|Cerebrovascular Disorders/classification/*complications/diagnosis/drug therapy[MESH]|Clinical Trials as Topic[MESH]|Diagnostic Tests, Routine[MESH]|Disease Management[MESH]|Fibrinolytic Agents/adverse effects/therapeutic use[MESH]|Heart Diseases/complications[MESH]|Humans[MESH]|Hypertension/complications[MESH]|Middle Aged[MESH]|Platelet Aggregation Inhibitors/adverse effects/therapeutic use[MESH]|Prospective Studies[MESH]|Secondary Prevention[MESH]|Thrombolytic Therapy/adverse effects[MESH]|Thrombophilia/complications/diagnosis/drug therapy[MESH]|Young Adult[MESH] |